Copyright Reports & Markets. All rights reserved.

Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Size Growth Rate by Product
      • 1.4.2 Pcr
      • 1.4.3 In Situ Hybridization
      • 1.4.4 Chips And Microarrays
      • 1.4.5 Isothermal Nucleic Acid Amplification Technology (Inaat)
      • 1.4.6 Mass Spectrometry
      • 1.4.7 Sequencing
      • 1.4.8 Transcription Mediated Amplification
    • 1.5 Market by End User
      • 1.5.1 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Size Growth Rate by End User
      • 1.5.2 Hospital
      • 1.5.3 Research
      • 1.5.4 Clinic
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Size
      • 2.1.1 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue 2014-2025
      • 2.1.2 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales 2014-2025
    • 2.2 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Growth Rate by Regions
      • 2.2.1 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales by Regions
      • 2.2.2 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales by Manufacturers
      • 3.1.1 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales by Manufacturers
      • 3.1.2 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales Market Share by Manufacturers
      • 3.1.3 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue by Manufacturers
      • 3.2.1 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue Share by Manufacturers (2014-2019)
    • 3.3 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Price by Manufacturers
    • 3.4 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Manufacturing Base Distribution, Product Types
      • 3.4.1 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Product Type
      • 3.4.3 Date of International Manufacturers Enter into Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales by Product
    • 4.2 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue by Product
    • 4.3 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Breakdown Data by End User

    6 North America

    • 6.1 North America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Countries
      • 6.1.1 North America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales by Countries
      • 6.1.2 North America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Product
    • 6.3 North America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by End User

    7 Europe

    • 7.1 Europe Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Countries
      • 7.1.1 Europe Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales by Countries
      • 7.1.2 Europe Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Product
    • 7.3 Europe Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Countries
      • 8.1.1 Asia Pacific Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales by Countries
      • 8.1.2 Asia Pacific Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Product
    • 8.3 Asia Pacific Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by End User

    9 Central & South America

    • 9.1 Central & South America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Countries
      • 9.1.1 Central & South America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales by Countries
      • 9.1.2 Central & South America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Product
    • 9.3 Central & South America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Countries
      • 10.1.1 Middle East and Africa Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales by Countries
      • 10.1.2 Middle East and Africa Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by Product
    • 10.3 Middle East and Africa Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment by End User

    11 Company Profiles

    • 11.1 Cepheid
      • 11.1.1 Cepheid Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Cepheid Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Cepheid Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.1.5 Cepheid Recent Development
    • 11.2 Beckton Dickinson
      • 11.2.1 Beckton Dickinson Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Beckton Dickinson Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Beckton Dickinson Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.2.5 Beckton Dickinson Recent Development
    • 11.3 Gen Probe (Hologic)
      • 11.3.1 Gen Probe (Hologic) Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Gen Probe (Hologic) Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Gen Probe (Hologic) Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.3.5 Gen Probe (Hologic) Recent Development
    • 11.4 Qiagen
      • 11.4.1 Qiagen Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Qiagen Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Qiagen Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.4.5 Qiagen Recent Development
    • 11.5 Roche
      • 11.5.1 Roche Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Roche Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Roche Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.5.5 Roche Recent Development
    • 11.6 Bayer Healthcare
      • 11.6.1 Bayer Healthcare Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Bayer Healthcare Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Bayer Healthcare Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.6.5 Bayer Healthcare Recent Development
    • 11.7 Dako
      • 11.7.1 Dako Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Dako Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Dako Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.7.5 Dako Recent Development
    • 11.8 Abbott Laboratories
      • 11.8.1 Abbott Laboratories Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Abbott Laboratories Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Abbott Laboratories Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.8.5 Abbott Laboratories Recent Development
    • 11.9 Danaher
      • 11.9.1 Danaher Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Danaher Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Danaher Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.9.5 Danaher Recent Development
    • 11.10 Siemens
      • 11.10.1 Siemens Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Siemens Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Siemens Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Products Offered
      • 11.10.5 Siemens Recent Development
    • 11.11 Sysmex
    • 11.12 Grifols
    • 11.13 Biomérieux

    12 Future Forecast

    • 12.1 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Forecast by Regions
      • 12.1.1 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue Forecast by Regions 2019-2025
    • 12.2 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Forecast by Product
      • 12.2.1 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Sales Forecast by Product 2019-2025
      • 12.2.2 Global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Revenue Forecast by Product 2019-2025
    • 12.3 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Market Forecast by End User
    • 12.4 North America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Forecast
    • 12.5 Europe Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Forecast
    • 12.6 Asia Pacific Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Forecast
    • 12.7 Central & South America Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Forecast
    • 12.8 Middle East and Africa Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Causal organism for infectious diseases could be bacteria, viruses, parasites or fungi and can be spread, directly or indirectly, from one person to another. Molecular diagnostic is showing promise in the identification of microorganisms as well as evaluation of virulence factors and antibiotic resistance determinants. Molecular infectious diseases diagnosis is moving towards high-throughput, simple, array-type technologies that provide a wealth of data on types of organisms present in a sample and the virulence factors/resistance determinants that influence the severity of disease. Molecular diagnostic helping infectious diseases to be more accurately and effectively treated.
      The global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment market based on company, product type, end user and key regions.

      This report studies the global market size of Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment in these regions.
      This research report categorizes the global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment market by top players/brands, region, type and end user. This report also studies the global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Cepheid
      Beckton Dickinson
      Gen Probe (Hologic)
      Qiagen
      Roche
      Bayer Healthcare
      Dako
      Abbott Laboratories
      Danaher
      Siemens
      Sysmex
      Grifols
      Biomérieux

      Market size by Product
      Pcr
      In Situ Hybridization
      Chips And Microarrays
      Isothermal Nucleic Acid Amplification Technology (Inaat)
      Mass Spectrometry
      Sequencing
      Transcription Mediated Amplification
      Market size by End User
      Hospital
      Research
      Clinic

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Molecular Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (NG) Diagnostic Equipment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now